Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a consent form and follow the study rules
- You are 18 years of age or older
- You have been diagnosed with a type of blood cancer called CD20+ B-cell Non-Hodgkin Lymphoma that came back or did not respond to at least one previous treatment that included a specific type of cancer-fighting drug (anti-CD20 antibody), and there are no other treatments expected to help extend your life
- You are generally able to carry out daily activities with little to no limitation (confirm with trial site)
- Your doctor expects you to live for at least 3 more months
- You have at least one measurable area of disease that is large enough to be tracked on scans (confirm with trial site for exact size requirements)
- Your blood counts, liver, and kidneys are functioning well enough to meet the study's requirements (confirm with trial site)
Who may not be able to join:
- You have been diagnosed with certain specific types of blood cancers, including chronic lymphoblastic leukemia, Burkitt lymphoma, or lymphoplasmacytic lymphoma
- You have a history of lymphoma or other disease affecting your brain or spinal cord
- You currently have an active infection of any kind (except minor fungal nail infections)
- You have received cancer treatments such as chemotherapy, radiation, immunotherapy, or surgery within the last 28 days before starting the study
- You have an active or suspected condition where your immune system attacks your own body (autoimmune disease)
- You have had a serious allergic reaction or a bad reaction to a monoclonal antibody treatment in the past
- You have another serious uncontrolled medical condition
- You have had major surgery within the last 28 days, or are expected to need major surgery during the study
- You have been diagnosed with another type of invasive cancer within the past 3 years
- You have a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML)
- You have a severe bleeding disorder such as hemophilia A, hemophilia B, or another condition causing serious uncontrolled bleeding
- You have HIV, hepatitis B, or hepatitis C (confirm with trial site for specific test result details)
- You are pregnant or currently breastfeeding; women who could become pregnant must agree to use two reliable forms of birth control, or to avoid sexual contact with men, both during the study and for at least 12 months after finishing all study treatments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase I：Percentage of Participants with Adverse Events (AEs); Phase I：Incidence of Dose Limiting Toxicities (DLTs); Phase I：Maximum Tolerated Dose (MTD) of MBS303; Phase I：Recommended Phase Ⅱ Dose (RP2D) of MBS303; Phase Ⅱ ：Antitumor activity as measured by the objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.